<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; World</title>
	<atom:link href="http://www.tapanray.in/tag/world/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why Is ‘Empathy’ Central In Pharma’s Digital World?</title>
		<link>http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-is-empathy-central-in-pharmas-digital-world</link>
		<comments>http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/#comments</comments>
		<pubDate>Mon, 21 Mar 2022 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[Central]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Metamorphosis]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[service]]></category>
		<category><![CDATA[talk-at]]></category>
		<category><![CDATA[talk-with]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10672</guid>
		<description><![CDATA[While pharma industry’s late realization of its slower pace of reform is widely criticized, it did demonstrate a resilience in facing several challenges of change, caused by Covid-19 pandemic to keep the business going. This was witnessed in many areas of customer-value delivery &#8230; <a href="http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-is-empathy-central-in-pharmas-digital-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Covid’s Second Wave ‘A Nation In Distress’ &#8211; Why?</title>
		<link>http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-covids-second-wave-a-nation-in-distress-why</link>
		<comments>http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/#comments</comments>
		<pubDate>Mon, 19 Apr 2021 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[A Nation in distress]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[clinically]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[proven]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Second]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[wave]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10475</guid>
		<description><![CDATA[If someone tries to see a silver lining in the disruptive Covid-19 pandemic, besides its vaccine rollout in some countries, there will be at least one. As of April 17, 2021- over 119 million patients (India &#8211; over 12 million), reportedly, &#8230; <a href="http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-covids-second-wave-a-nation-in-distress-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shape of Future Pharma Operations – Emerging A Pragmatic Outlook?</title>
		<link>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shape-of-future-pharma-operations-emerging-a-pragmatic-outlook</link>
		<comments>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/#comments</comments>
		<pubDate>Mon, 12 Apr 2021 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[communication]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[F2F]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hybrid]]></category>
		<category><![CDATA[in-person]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[MR]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[omnichannel]]></category>
		<category><![CDATA[operations]]></category>
		<category><![CDATA[outlook]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[Pragmatic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[role]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10468</guid>
		<description><![CDATA[Just as newer reports come almost every day on safety, efficacy, dosage interval or span of immunity of Covid vaccines, similar reports are also reaching us about the possible future shape of pharma sales and marketing operations. Some hardcore optimists, &#8230; <a href="http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shape-of-future-pharma-operations-emerging-a-pragmatic-outlook/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>How Pharma To Stay Relevant To Customers In The New Digital World</title>
		<link>http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world</link>
		<comments>http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/#comments</comments>
		<pubDate>Mon, 15 Mar 2021 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[brand managers]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[customer experience managers]]></category>
		<category><![CDATA[customer-relationship]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[employees]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intelligent]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[members]]></category>
		<category><![CDATA[new normal]]></category>
		<category><![CDATA[old normal]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[realigning]]></category>
		<category><![CDATA[redefine]]></category>
		<category><![CDATA[relevant]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[staff]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[work]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10441</guid>
		<description><![CDATA[Covid-19 vaccination has commenced in India on January 16, 2021, as in several other countries of the world. A few million Indians, across the country have already received their first shot, according to media reports. But, this isn’t the endgame of &#8230; <a href="http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/how-pharma-to-stay-relevant-to-customers-in-the-new-digital-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid Propels Healthcare Into A Virtual World: A New Growth Driver For Pharma?</title>
		<link>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma</link>
		<comments>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/#comments</comments>
		<pubDate>Mon, 19 Oct 2020 00:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[consultation]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[e-commerce]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[propels]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote]]></category>
		<category><![CDATA[strategies]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[virtual]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10299</guid>
		<description><![CDATA[Amid ongoing Covid pandemic, most discussions on pharma specific ‘digitalization’ initiatives continue to predominantly hover around its traditional business growth drivers. In fact, even before the Covid time, it was no different, in a smaller scale and with a lesser &#8230; <a href="http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-propels-healthcare-into-a-virtual-world-a-new-growth-driver-for-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Shifting Pharma Supply Chain Strategy From Global To Local</title>
		<link>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=shifting-pharma-supply-chain-strategy-from-global-to-local</link>
		<comments>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/#comments</comments>
		<pubDate>Mon, 08 Jun 2020 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[lobbyists]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Procurement]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reevaluating]]></category>
		<category><![CDATA[shifting]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vulnerability]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10120</guid>
		<description><![CDATA[Alongside large-scale disruptions of many critical industrial operations, Covid-19 global pandemic took the wind out of the sail of pharma supply chain, as well, at the very onset of lockdowns. This happened in many countries around the world, including the &#8230; <a href="http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/shifting-pharma-supply-chain-strategy-from-global-to-local/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>UCPMP: Vacillating Between ‘The Perfect’ And ‘The Real’ World?</title>
		<link>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=ucpmp-vacillating-between-the-perfect-and-the-real-world</link>
		<comments>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/#comments</comments>
		<pubDate>Mon, 02 Mar 2020 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[PM]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[Uniform]]></category>
		<category><![CDATA[Vacillating]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[‘The Perfect’]]></category>
		<category><![CDATA[‘The Real’]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9896</guid>
		<description><![CDATA[In the ‘perfect world’ one takes ‘perfect decisions’, while in the ‘real world’ one takes a ‘real decision’ &#8211; as the saying goes. In tandem, a raging debate continues on what is ‘perfect’ and what is ‘real’, in the world &#8230; <a href="http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/ucpmp-vacillating-between-the-perfect-and-the-real-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Honing Patient Outcomes With WHDs</title>
		<link>http://www.tapanray.in/hoing-patient-outcomes-with-whds/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=hoing-patient-outcomes-with-whds</link>
		<comments>http://www.tapanray.in/hoing-patient-outcomes-with-whds/#comments</comments>
		<pubDate>Mon, 02 Dec 2019 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Democratization]]></category>
		<category><![CDATA[Devices]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Fitbit]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[honing]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Internet]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[penetration]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[smartphone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[wearable]]></category>
		<category><![CDATA[Wearables]]></category>
		<category><![CDATA[WHD]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9791</guid>
		<description><![CDATA[On November 01, 2019, San Francisco-based Fitbit, Inc. announced that it has entered into a definitive agreement to be acquired by Google LLC for approximately US$ 2.1 billion. Many believe, though, the value of Fitbit lies in the health data that its &#8230; <a href="http://www.tapanray.in/hoing-patient-outcomes-with-whds/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/hoing-patient-outcomes-with-whds/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dynamics of Cancer Therapy Segment Remain Enigmatic</title>
		<link>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dynamics-of-cancer-therapy-segment-remain-enigmatic</link>
		<comments>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/#comments</comments>
		<pubDate>Mon, 14 Oct 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Assistance]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[enigma]]></category>
		<category><![CDATA[enigmatic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[PAP]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[program]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UICC]]></category>
		<category><![CDATA[Union for International Cancer Control]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9745</guid>
		<description><![CDATA[Currently, cancer is likely to occupy the center stage on any discussion related to the fastest growing therapy segments in the pharma or biotech industries. There are several reasons behind such probability, some of which include: Cancer is not only &#8230; <a href="http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is India in The Eye of The AMR Storm?</title>
		<link>http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-india-in-the-eye-of-the-amr-storm</link>
		<comments>http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/#comments</comments>
		<pubDate>Mon, 26 Aug 2019 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[AMR capital]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[Antimicrobial]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Eye of the storm]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[menace]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[sociocultural]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9684</guid>
		<description><![CDATA[‘With 700,000 people losing battle to antimicrobial resistance (AMR) per year and another 10 million projected to die from it by 2050, AMR alone is killing more people than cancer and road traffic accidents combined together.’ This was highlighted in &#8230; <a href="http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-india-in-the-eye-of-the-amr-storm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
